{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:47:25Z","timestamp":1785466045875,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,5,11]]},"DOI":"10.1038\/s41416-021-01313-0","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T07:02:45Z","timestamp":1616569365000},"page":"1647-1652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The added value of H2 antagonists in premedication regimens during paclitaxel treatment"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-1090","authenticated-orcid":false,"given":"Juul M.","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leni","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa M.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M. L. A.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-6030","authenticated-orcid":false,"given":"Roelof W. F.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1313_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","volume":"90","author":"J Szebeni","year":"1998","unstructured":"Szebeni, J., Muggia, F. M. & Alving, C. R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl Cancer Inst. 90, 300\u2013306 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/cea.12708","volume":"46","author":"KH Park","year":"2016","unstructured":"Park, K. H., Pai, J., Song, D. G., Sim, D. W., Park, H. J., Lee, J. H. et al. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing. Clin. Exp. Allergy 46, 631\u2013639 (2016).","journal-title":"Clin. Exp. Allergy"},{"issue":"Suppl. 10","key":"1313_CR3","doi-asserted-by":"publisher","first-page":"x313","DOI":"10.1093\/annonc\/mds314","volume":"23","author":"M Joerger","year":"2012","unstructured":"Joerger, M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann. Oncol. 23 (Suppl. 10), x313\u2013x319 (2012).","journal-title":"Ann. Oncol."},{"key":"1313_CR4","unstructured":"Bristol-Meyers Squibb. Taxol (Paclitaxel) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf (2020)."},{"key":"1313_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1040-8428(00)00112-8","volume":"37","author":"H Choy","year":"2001","unstructured":"Choy, H. Taxanes in combined modality therapy for solid tumors. Crit. Rev. Oncol. Hematol. 37, 237\u2013247 (2001).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1313_CR6","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel, W. H. Infusion reactions: diagnosis, assessment, and management. Clin. J. Oncol. Nurs. 14, E10\u2013E21 (2010).","journal-title":"Clin. J. Oncol. Nurs."},{"key":"1313_CR7","unstructured":"Common Terminology Criteria for Adverse Events, version 4.0, published 28 May 2009 (v4.03: 14 June 2010) (2020). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_4.03.xlsx."},{"key":"1313_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., Belinson, J. et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J. Clin. Oncol. 18, 102\u2013105 (2000).","journal-title":"J. Clin. Oncol."},{"key":"1313_CR9","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jaci.2010.11.047","volume":"127","author":"A Romano","year":"2011","unstructured":"Romano, A., Torres, M. J., Castells, M., Sanz, M. L. & Blanca, M. Diagnosis and management of drug hypersensitivity reactions. J. Allergy Clin. Immunol. 127, S67\u2013S73 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clinthera.2015.12.009","volume":"38","author":"H Nokihara","year":"2016","unstructured":"Nokihara, H., Yamamoto, N., Ohe, Y., Hiraoka, M. & Tamura, T. Pharmacokinetics of weekly paclitaxel and feasibility of dexamethasone taper in Japanese patients with advanced non-small cell lung cancer. Clin. Ther. 38, 338\u2013347 (2016).","journal-title":"Clin. Ther."},{"key":"1313_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1023\/A:1008207025430","volume":"8","author":"MA Bookman","year":"1997","unstructured":"Bookman, M. A., Kloth, D. D., Kover, P. E., Smolinski, S. & Ozols, R. F. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann. Oncol. 8, 611\u2013614 (1997).","journal-title":"Ann. Oncol."},{"key":"1313_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L. et al. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263\u20131268 (1990).","journal-title":"J. Clin. Oncol."},{"key":"1313_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s004320050297","volume":"125","author":"M Markman","year":"1999","unstructured":"Markman, M., Kennedy, A., Webster, K., Peterson, G., Kulp, B., Belinson, J. et al. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J. Cancer Res. Clin. Oncol. 125, 427\u2013429 (1999).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1313_CR14","doi-asserted-by":"crossref","unstructured":"Berger, M. J., Vargo, C., Vincent, M., Shaver, K., Phillips, G., Layman, R. et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23, 2019\u20132024 (2015).","DOI":"10.1007\/s00520-014-2556-x"},{"key":"1313_CR15","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/ijc.21680","volume":"118","author":"H Yahata","year":"2006","unstructured":"Yahata, H., Saito, M., Sendo, T., Itoh, Y., Uchida, M., Hirakawa, T. et al. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int. J. Cancer 118, 2636\u20132638 (2006).","journal-title":"Int. J. Cancer"},{"key":"1313_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0091-6749(81)90059-2","volume":"67","author":"PA Greenberger","year":"1981","unstructured":"Greenberger, P. A., Patterson, R., Simon, R., Lieberman, P. & Wallace, W. Pretreatment of high-risk patients requiring radiographic contrast media studies. J. Allergy Clin. Immunol. 67, 185\u2013187 (1981).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1313_CR17","unstructured":"Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B. & Paietta, E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47, 2486\u20132493 (1987)."},{"key":"1313_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1001\/archinte.1985.00360120065011","volume":"145","author":"PA Greenberger","year":"1985","unstructured":"Greenberger, P. A., Patterson, R. & Tapio, C. M. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch. Intern. Med. 145, 2197\u20132200 (1985).","journal-title":"Arch. Intern. Med."},{"key":"1313_CR19","unstructured":"Cook, J. & Shuster, S. Lack of effect of H2 blockade in chronic urticaria [proceedings. Br. J. Dermatol. 101 (Suppl. 17), 21\u201322 (1979)."},{"key":"1313_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0091-6749(79)90094-0","volume":"64","author":"P Greenberger","year":"1979","unstructured":"Greenberger, P., Harris, K. & Patterson, R. The effect of histamine-1 and histamine-2 antagonists on airway responses to histamine in the rhesus monkey. J. Allergy Clin. Immunol. 64, 189\u2013196 (1979).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1313_CR21","first-page":"203","volume":"16","author":"K Demirkan","year":"2006","unstructured":"Demirkan, K., Bozkurt, B., Karakaya, G. & Kalyoncu, A. F. Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. J. Investig. Allergol. Clin. Immunol. 16, 203\u2013209 (2006).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"1313_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1365-4632.2010.04834.x","volume":"50","author":"TY Han","year":"2011","unstructured":"Han, T. Y., Jang, W. S., Yu, M., Lee, H. K., Son, S. J., Seo, S. J. et al. Anaphylactic reaction to ranitidine (Zantac(R)). Int. J. Dermatol. 50, 1397\u20131399 (2011).","journal-title":"Int. J. Dermatol."},{"key":"1313_CR23","unstructured":"HyLown.com. Power and sample size calculator (2020). http:\/\/powerandsamplesize.com\/Calculators\/."},{"key":"1313_CR24","unstructured":"R Core Team (2013). R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2019)."},{"key":"1313_CR25","first-page":"283","volume":"24","author":"H Koppler","year":"2001","unstructured":"Koppler, H., Heymanns, J. & Weide, R. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24, 283\u2013285 (2001).","journal-title":"Onkologie"},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s10147-007-0675-9","volume":"12","author":"S Sasada","year":"2007","unstructured":"Sasada, S., Hirashima, T., Nakamura, Y., Takimoto, T., Furukawa, M., Kobayashi, M. et al. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions. Int. J. Clin. Oncol. 12, 274\u2013278 (2007).","journal-title":"Int. J. Clin. Oncol."},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U","volume":"74","author":"JD Hainsworth","year":"1994","unstructured":"Hainsworth, J. D. & Greco, F. A. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I\/II trial comparing two schedules. Cancer 74, 1377\u20131382 (1994).","journal-title":"Cancer"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-017-3332-7","volume":"80","author":"T Aoyama","year":"2017","unstructured":"Aoyama, T., Takano, M., Miyamoto, M., Yoshikawa, T., Soyama, H., Kato, K. et al. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?. Cancer Chemother. Pharmacol. 80, 65\u201369 (2017).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01313-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T15:03:10Z","timestamp":1658329390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01313-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,5,11]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01313-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the medical ethical board of the Erasmus MC, reference number MEC-2018-1499. All included patients gave informed consent. This study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data supporting the findings of this study are available within the article and its information files and from the corresponding author upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"R.H.J.M. reports research grants from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Pfizer, Prostakan, Roche and Pamgene. Personal fees from Novartis and Servier; all outside the submitted work. R.W.F.v.L. reports research grants from Astellas, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Servier and Roche. Personal fees from Roche, Pfizer and Sanofi; all outside the submitted work. All other authors declare no potential competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was funded by the Foundation Mitialto in the Netherlands. Foundation Mitialto had no role in any aspect of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}